Pharmaceutical startups today operate in a landscape shaped by scientific innovation and increasing expectations around sustainability and transparency. 

When Pfizer declared in 2022 that it would reach net-zero greenhouse-gas emissions by 2040, slashing its own footprint by 95 % and its value-chain emissions by 90 % from 2019 levels, the announcement did more than burnish a blue-chip brand. 

It crystallized a sector-wide pivot! Investors, regulators, customers, and talent now expect even the smallest firms to weave Environmental, Social, and Governance (ESG) principles into their very DNA. 

Even for early-stage pharma companies, integrating ESG has become a competitive necessity. 

But then the question is how exactly ESG would benefit these pharma startups.

The sections that follow map five critical pathways—from influencing investment decisions to attracting top talent—showing why startups that build sustainability early will be the ones that endure and excel.

1. ESG Practices Influence Investment Decisions

Investors are increasingly looking at ESG metrics when making funding decisions. Multiple industry reports confirm that venture capital and institutional investors are incorporating ESG factors into their due diligence processes, reflecting a growing demand for sustainability and transparency

3one4 Capital, a Bengaluru-based venture capital firm, has institutionalized ESG practices across its investments. They have developed an Early Stage ESG Score (ES2) to evaluate ESG performance during the pre-investment stage. Their portfolio includes companies like Dozee (healthcare technology), Licious (sustainable food industry), and Yulu (electric vehicle adoption), reflecting a commitment to sustainable growth.

2. ESG Lowers Operational Risk and the Cost of Capital

Pharmaceutical manufacturing carries a significant environmental footprint. A study from McMaster University found that in 2015, the pharma sector emitted 55% more carbon per dollar of revenue than the automotive industry.

Startups that implement sustainable operations early can minimize future regulatory burdens and secure more favorable financing.

Companies like Amgen are setting industry benchmarks by integrating sustainable manufacturing practices and committing to measurable milestones, such as reducing carbon emissions by 70% by 2030. 

3. Access to Non-Dilutive and Grant Funding

Pharma startups that align with ESG principles are eligible for a broader range of funding opportunities, especially from public sector programs, international agencies, and philanthropic organizations.

Government-backed programs such as the European Union’s Horizon Europe, the U.S. National Institutes of Health (NIH), and the Gates Foundation increasingly prioritize sustainability, ethical research, and community impact as funding criteria.

Access to this kind of funding can reduce financial pressure, extend the operational runway, and enhance a startup’s reputation among other stakeholders.

By embedding ESG goals into core business strategies, startups position themselves as strong candidates for future rounds of mission-aligned support.

4. Partners and Buyers Are Setting ESG Requirements

Governments and public health systems are introducing formal ESG requirements for pharmaceutical suppliers. In the UK, the National Health Service (NHS) has set a roadmap for supplier decarbonization. By 2027, all suppliers of medicines must publish carbon-reduction plans to continue doing business with the NHS (NHS England, 2023).

In India, regulatory momentum is also building. As of 2024, around 38% of Indian pharmaceutical companies have published standalone ESG or sustainability reports. The Securities and Exchange Board of India (SEBI) has made it mandatory for the top 1,000 listed companies to file Business Responsibility and Sustainability Reports (BRSR), covering ESG performance in a standardized format (SEBI, 2021).

Government-led initiatives such as the National Biopharma Mission, PLI schemes, and support from BIRAC are also promoting ESG-aligned innovation. These programs incentivize sustainable manufacturing, responsible research, and broader compliance with global ESG standards.

5. How Startups Can Begin ESG Integration

Even small teams can make meaningful progress on ESG by using accessible tools and targeted strategies. Environmentally, platforms like Altruistiq help track and reduce emissions, while switching to recyclable or low-impact lab consumables supports sustainability reporting. 

Social impact improves through more inclusive clinical trials using remote tools to reach underrepresented populations—enhancing both equity and regulatory success. 

For governance, adopting standards like SASB or registering as a Public Benefit Corporation demonstrates transparency and long-term commitment. Tools like SpheraCloud and Planetly also offer ESG tracking solutions fit for startups. These steps not only meet ESG goals but also build lasting value and resilience.

The Outlook

ESG is now the credibility benchmark for life-science startups. Founders who weave measurable ESG targets into their operating plans derisk future compliance costs, widen their funding funnel with access to green bonds and mission-aligned grants, and improve margins through resource-efficient processes.

Well-chosen metrics, such as carbon-per-dose manufactured, percentage of clinical-trial participants from underrepresented groups, and board independence ratios, become proof points that can be audited, reported, and celebrated.

The inflection point is now. By building sustainability frameworks while their organizations are still agile, pharma startups can lock in long-term advantages that incumbents must retrofit at great expense. Those that move early will not merely keep pace with regulation and investor sentiment—they will set the benchmarks that others scramble to meet.

Edited by Harshajit Sarmah